Statins and hepatotoxicity: focus on patients with fatty liver.
about
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsStatin adverse effects : a review of the literature and evidence for a mitochondrial mechanismNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementTreatment of non-alcoholic fatty liver diseasePleiotropic effects of statins in the diseases of the liverManagement of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver diseaseBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesPrimary biliary cirrhosis: Pathophysiology, clinical presentation and therapyStrategies to rescue steatotic livers before transplantation in clinical and experimental studiesDrug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury networkStatins and their interactions with other lipid-modifying medications: safety issues in the elderlyEpidemiology of idiosyncratic drug-induced liver injuryTreatment options for nonalcoholic Fatty liver diseaseManagement of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients.Nonalcoholic fatty liver disease and aging: epidemiology to management.Pathogenesis and therapeutic approaches for non-alcoholic fatty liver diseaseStatin use in patients with cirrhosis: a retrospective cohort study.Treating statin-intolerant patientsLipid-lowering agents that cause drug-induced hepatotoxicity.An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).Focus on therapeutic strategies of nonalcoholic Fatty liver diseaseHepatotoxicity Associated with a Short Course of Rosuvastatin.Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study.Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.Dyslipidemia in patients with nonalcoholic fatty liver disease.How should we manage patients with non-alcoholic fatty liver disease in 2007?Present and future therapeutic strategies in non-alcoholic fatty liver disease.The safety of rosuvastatin: effects on renal and hepatic function.Pathophysiological Significance of Hepatic ApoptosisNonalcoholic fatty liver disease and diabetes mellitus.Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension.Medical Care of the Patient With Compensated Cirrhosis.
P2860
Q22299426-77991717-FAE3-4BFD-A17F-15BF9ED75036Q24603957-9133B5FF-839E-4B18-9A95-CAE1D506BEA5Q24649618-9686375F-CBA9-4C6F-91FE-79853E128AC4Q24655572-932C785F-04E4-4C8F-9B4C-E40EA33B96D5Q26741176-81B219B6-CE23-4FC1-AF25-BE0F7F0E0540Q26827665-07E78538-7B55-47D8-84B2-C074E7A65E63Q26853571-73A67B28-6A76-4CAF-8C66-67828D1F27E7Q26853649-DF64B561-6BF3-44F3-A439-C60D5458E0B4Q27003912-A8176F60-2AE2-428B-95A1-2A9CE34B7DB2Q30241648-EF8F950B-CDC4-4CE4-869E-6333DCFEE1ACQ33765060-8E89CB00-9BFE-4CAA-897D-FD0F9B75B3B2Q33946592-947DD8D6-3F11-4452-8EFF-825E0DE01128Q33949348-DC852C52-DA39-4132-ADCC-F614DF637FF0Q33990236-991306BD-8D50-431F-B1AD-85AC7AF324F2Q34156317-4E2C23D0-2E45-4AF7-B037-F71DF1380B91Q34168532-31D22F82-E246-455C-85FC-0C4AF1D7051BQ34169932-5ECEA8EC-3CBA-493D-AEF2-7E60053A9334Q34366861-1B0945E6-AD6E-41CF-AA1D-B0200013D434Q34449857-5522747D-058F-46B6-8338-F09F9E4E57B5Q34661975-FAC6AC1E-C2FE-4066-A5C7-496978BAD3E6Q35110510-28BB9214-92A3-4A7A-9DE7-B951AF1BD363Q36103339-FF712FB4-311E-45A1-89E4-790D0F3DEEFCQ36328050-FF53F3EA-6F9F-437F-8FCD-4A1E691AFF3BQ36413703-A9695505-8A48-48EA-AAD0-85BE2C217A48Q36523234-C2DB6ED3-A839-4E59-9E50-464FF3030DC4Q36593266-378A245F-EE37-4DE8-B194-B9234D865990Q36654473-15DEB83C-4B54-4B37-8F4A-C91998FEB036Q36726951-7B4014C7-D81C-40F6-BE4A-441E53D0B442Q36818351-762629CF-0472-40C2-8EDC-C5C364529261Q36837171-2FA6760E-EF17-417C-835B-DD307DEC6574Q36845703-03A50986-B391-4EFA-9D38-90F65AE5BE36Q36848280-360F8E40-FA3E-4A31-854A-3F7E9E5547B6Q36936358-1F681468-902D-47DA-9782-B8FB13139CE2Q36945023-9545CE4A-5248-4F40-A1B1-B299A5BB256FQ36961965-1504273A-2D96-48F8-88CA-7E1634A74274Q37037458-7D5FFBFC-B2D5-4FDF-8004-2E90F0F2E57AQ37465565-6D098EC4-C4A0-421C-AF34-14A8F9B86212Q37554404-98E6FCA8-A76B-4DA5-AEBF-E549921C9D0BQ37651909-568DCA7B-A518-4890-97BC-BF4DEE05656FQ37678908-24E725A9-F441-4FDD-AB1F-D333E4579584
P2860
Statins and hepatotoxicity: focus on patients with fatty liver.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Statins and hepatotoxicity: focus on patients with fatty liver.
@ast
Statins and hepatotoxicity: focus on patients with fatty liver.
@en
type
label
Statins and hepatotoxicity: focus on patients with fatty liver.
@ast
Statins and hepatotoxicity: focus on patients with fatty liver.
@en
prefLabel
Statins and hepatotoxicity: focus on patients with fatty liver.
@ast
Statins and hepatotoxicity: focus on patients with fatty liver.
@en
P356
P1433
P1476
Statins and hepatotoxicity: focus on patients with fatty liver.
@en
P2093
Naga Chalasani
P304
P356
10.1002/HEP.20671
P407
P577
2005-04-01T00:00:00Z